Evidence map›Paper›PMID 36752844›Full record

ArticleAnnals of hematology2023

Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma.

Shanshan Liu, Hongwei Zhou, Weiling Xu, Tao Jin, Xinyue Liang, Xiaoxia Zhao, Yun Dai, Fengyan Jin

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shanshan Liu *Hematology Department, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Hongwei Zhou *Radiology Department, First Hospital of Jilin University, Changchun, Jilin, China.
Weiling Xu *Radiology Department, First Hospital of Jilin University, Changchun, Jilin, China.
Tao JinNeurology Department, First Hospital of Jilin University, Changchun, Jilin, China.
Xinyue LiangHematology Department, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Xiaoxia ZhaoHematology Department, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.
Yun DaiLaboratory of Cancer Precision Medicine, First Hospital of Jilin University, 519 Dongminzhu Street, Changchun, 130061, Jilin, China. daiyun@jlu.edu.cn.ORCID http://orcid.org/0000-0003-2285-0818
Fengyan JinHematology Department, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China. fengyanjin@jlu.edu.cn.ORCID http://orcid.org/0000-0003-2288-556X
Jilin University · CN

Funding

Jilin Scientific and Technological Development Program 20190201042JCJilin Scientific and Technological Development Program 20190201163JCJilin Scientific and Technological Development Program 20210509010RQNational Natural Science Foundation of China 81471165National Natural Science Foundation of China 81670189National Natural Science Foundation of China 81670190National Natural Science Foundation of China 81870160National Natural Science Foundation of China 81971108National Natural Science Foundation of China 82270207
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHumansLenalidomideAntibodies, MonoclonaldaratumumabLenalidomide

Identifiers

PMID36752844
PMCPMC9907188
OpenAlexW4319455222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.